Phenotypic Test of Benzo[4,5]imidazo[1,2-c]pyrimidinone-Based Nucleoside and Non-Nucleoside Derivatives against DNA and RNA Viruses, Including Coronaviruses
作者:Polina Kamzeeva、Ivan Petushkov、Ekaterina Knizhnik、Robert Snoeck、Yuri Khodarovich、Ekaterina Ryabukhina、Vera Alferova、Artur Eshtukov-Shcheglov、Evgeny Belyaev、Julia Svetlova、Tatiana Vedekhina、Andrey Kulbachinskiy、Anna Varizhuk、Graciela Andrei、Andrey Aralov
DOI:10.3390/ijms241914540
日期:——
urgent need for new antiviral drugs is obvious. Over more than a century of antiviral development, nucleoside analogs have proven to be promising agents against diversified DNA and RNA viruses. Here, we present the synthesis and evaluation of the antiviral activity of nucleoside analogs and their deglycosylated derivatives based on a hydroxybenzo[4,5]imidazo[1,2-c]pyrimidin-1(2H)-one scaffold. The antiviral
新出现和重新出现的病毒会定期在世界各地引起爆发和流行,最终导致 COVID-19 大流行等全球事件。由此可见,对新型抗病毒药物的迫切需求是显而易见的。经过一个多世纪的抗病毒发展,核苷类似物已被证明是对抗多种 DNA 和 RNA 病毒的有前途的药物。在这里,我们介绍了基于羟基苯并[4,5]咪唑并[1,2-c]嘧啶-1(2H)-one支架的核苷类似物及其去糖基化衍生物的抗病毒活性的合成和评估。针对一组结构和系统发育多样化的 RNA 和 DNA 病毒评估了抗病毒活性。该先导化合物对冠状病毒科的代表(包括 SARS-CoV-2)以及亚微摩尔范围内的呼吸道合胞病毒表现出微摩尔活性,且对宿主细胞没有明显毒性。令人惊讶的是,先导化合物的芳香羟基的甲基化导致针对水痘带状疱疹病毒的微摩尔活性,且对细胞活力没有任何显着影响。该先导化合物被证明是 SARS-CoV-2 RNA 依赖性 RNA 聚合酶的弱抑制剂。它还抑制对